In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Josh Gad opened up about losing 40 pounds since he began taking GLP-1 medication, the class of drug that includes Ozempic ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

The presentation scheduled for Tuesday, February 11th at 12:40-1:10 PM ET in Track 1 will feature a business overview and update by Miranda Toledano, the Company’s Chief Executive Officer.

Only a tiny percentage of people addicted to alcohol or drugs take medication for it. Why not? It's complicated, but the ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...